{"filing":{"accession_number":"0001493152-26-035665","cik":"0001904286","ticker":"MIRA","company_name":"MIRA PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-27","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226035665/form8-k.htm"},"events":[{"id":22467,"run_id":20323,"accession_number":"0001493152-26-035665","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Mira Pharmaceuticals received a notice from Nasdaq on July 27, 2026, that it failed to maintain the minimum bid price of $1 per share under Nasdaq Listing Rule 5550(a)(2). The company has been given 180 calendar days until January 25, 2027, to regain compliance, with the explicit warning that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":22418,"accession_number":"0001493152-26-035665","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Mira Pharmaceuticals received a notice from Nasdaq on July 27, 2026, that it failed to maintain the minimum bid price of $1 per share under Nasdaq Listing Rule 5550(a)(2). The company has been given 180 calendar days until January 25, 2027, to regain compliance, with the explicit warning that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:24:34.583976+00:00","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-07-31"}]}